46 related articles for article (PubMed ID: 38554155)
21. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
22. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
23. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Keskin DB; Anandappa AJ; Sun J; Tirosh I; Mathewson ND; Li S; Oliveira G; Giobbie-Hurder A; Felt K; Gjini E; Shukla SA; Hu Z; Li L; Le PM; Allesøe RL; Richman AR; Kowalczyk MS; Abdelrahman S; Geduldig JE; Charbonneau S; Pelton K; Iorgulescu JB; Elagina L; Zhang W; Olive O; McCluskey C; Olsen LR; Stevens J; Lane WJ; Salazar AM; Daley H; Wen PY; Chiocca EA; Harden M; Lennon NJ; Gabriel S; Getz G; Lander ES; Regev A; Ritz J; Neuberg D; Rodig SJ; Ligon KL; Suvà ML; Wucherpfennig KW; Hacohen N; Fritsch EF; Livak KJ; Ott PA; Wu CJ; Reardon DA
Nature; 2019 Jan; 565(7738):234-239. PubMed ID: 30568305
[TBL] [Abstract][Full Text] [Related]
24. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review.
Wang S; Huang S; Sun YL
Biomed Res Int; 2017; 2017():2646148. PubMed ID: 29379795
[TBL] [Abstract][Full Text] [Related]
26. Robust enumeration of cell subsets from tissue expression profiles.
Newman AM; Liu CL; Green MR; Gentles AJ; Feng W; Xu Y; Hoang CD; Diehn M; Alizadeh AA
Nat Methods; 2015 May; 12(5):453-7. PubMed ID: 25822800
[TBL] [Abstract][Full Text] [Related]
27. Tumoricidal activity of human dendritic cells.
Tel J; Anguille S; Waterborg CE; Smits EL; Figdor CG; de Vries IJ
Trends Immunol; 2014 Jan; 35(1):38-46. PubMed ID: 24262387
[TBL] [Abstract][Full Text] [Related]
28. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.
Wang CJ; Wang C; Han J; Wang YK; Tang L; Shen DW; Zhao Y; Xu RH; Zhang H
Mol Biol Rep; 2013 Dec; 40(12):6579-85. PubMed ID: 24135803
[TBL] [Abstract][Full Text] [Related]
29. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
30. What is recent in pancreatic cancer immunotherapy?
Niccolai E; Prisco D; D'Elios MM; Amedei A
Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
[TBL] [Abstract][Full Text] [Related]
31. Current immunotherapeutic approaches in pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Tsukinaga S; Mitobe J; Odahara S; Yukawa T; Matsudaira H; Nagatsuma K; Uchiyama K; Satoh K; Ito M; Komita H; Arakawa H; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2011; 2011():267539. PubMed ID: 21922022
[TBL] [Abstract][Full Text] [Related]
32. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
33. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
[TBL] [Abstract][Full Text] [Related]
34. CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities.
Yanagawa Y; Onoé K
Blood; 2003 Jun; 101(12):4923-9. PubMed ID: 12609829
[TBL] [Abstract][Full Text] [Related]
35. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Atkins MB; Lotze MT; Dutcher JP; Fisher RI; Weiss G; Margolin K; Abrams J; Sznol M; Parkinson D; Hawkins M; Paradise C; Kunkel L; Rosenberg SA
J Clin Oncol; 1999 Jul; 17(7):2105-16. PubMed ID: 10561265
[TBL] [Abstract][Full Text] [Related]
36. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
Fields RC; Shimizu K; Mulé JJ
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9482-7. PubMed ID: 9689106
[TBL] [Abstract][Full Text] [Related]
37. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions.
Jonuleit H; Kühn U; Müller G; Steinbrink K; Paragnik L; Schmitt E; Knop J; Enk AH
Eur J Immunol; 1997 Dec; 27(12):3135-42. PubMed ID: 9464798
[TBL] [Abstract][Full Text] [Related]
38. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
Sallusto F; Lanzavecchia A
J Exp Med; 1994 Apr; 179(4):1109-18. PubMed ID: 8145033
[TBL] [Abstract][Full Text] [Related]
39. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?
Grabbe S; Beissert S; Schwarz T; Granstein RD
Immunol Today; 1995 Mar; 16(3):117-21. PubMed ID: 7718082
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
